Fig. 5.

Training and test patient groups were used to generate and validate survival and recurrence compound predictor (CP) protein signatures. The CP was generated from the sum of the significant proteins in the training set, weighted by the proteins’ predictive ability, for both survival and recurrence. A) top: the patients in the training set were ranked and divided by their CP score into 2 groups: “poor” (med. survival ≤12 months) and “favorable” (med. survival >12 months). A) bottom: CP range for “poor” and “favorable” survival was evaluated in the test set, showing comparable median 12 month survival in the “poor” group. B) top: recurrence CP scores divided the training set into “favorable” (med. rec. >12 months) and into two poor groups: “poor” (med. rec.=8 months) and “poorer” (med. rec.=5 months). B) bottom: recurrence CP score evaluated in the test set, which successfully showed comparable “poor” (med. rec.=9 months) and “poorer” (med. rec.=4 months) groups, in line with the predicted score. *The “favorable” group in the recurrence test set was omitted for clarity, see text.